NCT05658913 Tau PET/CT Imaging in the Mismatch Prospective Cohort Study (MPC-TAU)
| NCT ID | NCT05658913 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Pennsylvania |
| Condition | Alzheimer's Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2023-03-14 |
| Primary Completion | 2027-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2023-03-14 with a primary completion date of 2027-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To collect Tau PET/CT imaging in older adults diagnosed with Mild Cognitive Impairment (MCI) or Alzheimer's Disease (AD) in the Mismatch Prospective Cohort Study (MPC-Tau) study to determine relationship to clinical, cognitive, and other biomarker data. Findings from this study will likely provide insight into the phenotypic variability of Alzheimer's Disease and other related pathologies.
Eligibility Criteria
Inclusion Criteria: 1. Enrolled in MPC study (Protocol 850160 at UPenn; Protocol 2022P002447 at MGH). 2. Reliable study partner to accompany participant to the PET/CT scan 3. A brain MRI must be performed within 6 months prior to their study AV-1451 TAU PET/CT scan date and be deemed of adequate quality that the scan may be used for study analysis, including 3T high-resolution imaging of medial temporal lobe structures. Exclusion Criteria: 1. Have any medical or psychiatric conditions that, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study. 2. Have evidence of structural abnormalities such as major stroke or mass on MRI that is likely to interfere with analysis of the PET/CT scan. 3. Inability to tolerate or contraindication to imaging procedures in the opinion of an investigator or treating physician. 4. Have a history of significant ongoing alcohol or substance abuse based on self- report. 5. Female participants of child-bearing age will not be able to participate in this study, determined by self-report.
Contact & Investigator
David A. Wolk
PRINCIPAL INVESTIGATOR
University of Pennsylvania Department of Neurology at the Perelman School of Medicine
Frequently Asked Questions
Who can join the NCT05658913 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 120 Years, studying Alzheimer's Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05658913 currently recruiting?
Yes, NCT05658913 is actively recruiting participants. Contact the research team at Jacqueline.Lane@pennmedicine.upenn.edu for enrollment information.
Where is the NCT05658913 trial being conducted?
This trial is being conducted at Boston, United States, Philadelphia, United States.
Who is sponsoring the NCT05658913 clinical trial?
NCT05658913 is sponsored by University of Pennsylvania. The principal investigator is David A. Wolk at University of Pennsylvania Department of Neurology at the Perelman School of Medicine. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.